Diagnosis of Prostate Cancer Recurrence with PSA Levels below 0.2 ng/ml with Intermittent Antiandrogen Therapy
Article Sidebar
Main Article Content
Abstract
Abstract
A case of investigation of a patient with recurrent prostate cancer after Radical Prostatectomy (RP) followed with 70 Gray irradiation (RT) due to numerous positive margins is reported. The Prostate Specific Antigen (PSA) level was fluctuating below 0.2 ng/mL. Comprehensive data on symptoms, Ultrasound (US) measurements, medical treatment, and PSA level fluctuations during intermittent Antiandrogen Therapy (ADT) were analyzed. ADT led to reduction in the size of the cancer by almost half. The PSA level decreased in accordance with the ADT injections. US with Doppler showed an area with increased blood flow. A nano-knife procedure was applied to this suspicious area. Then the Pfizer vaccine was administered, as a result of the final two treatments the PSA level dropped to 0,006 ng/ml. All the symptoms disappeared.
Downloads
Article Details
Copyright (c) 2025 Grytsenko K.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pal SK, Ruel N, Vogelzang N, Chang M, Wilson TG, Jones JO, et al. Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease. Clin Genitourin Cancer. 2014;12(3):149-54. Available from: https://doi.org/10.1016/j.clgc.2013.11.009
MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, et al. Mapping European Association of Urology guideline practice across Europe: an audit of androgen deprivation therapy use before prostate cancer surgery in 6598 cases in 187 hospitals across 31 European countries. Eur Urol. 2023;83:393-401. Available from: https://doi.org/10.1016/j.eururo.2022.12.031
Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging biochemical recurrence after prostatectomy: Where are we headed? AJR Am J Roentgenol. 2020;214(6). Available from: https://doi.org/10.2214/AJR.19.21905
Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, Carino D, et al. How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy. Cancers (Basel). 2024;16(4):764. Available from: https://doi.org/10.3390/cancers16040764
Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27:192-201. Available from: https://doi.org/10.1038/s41391-023-00712-z
Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol. 2014;66(2):204-10. Available from: https://doi.org/10.1016/j.eururo.2013.08.022
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part 1: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;11(4):509-17. Available from: https://mdanderson.elsevierpure.com/en/publications/salvage-therapy-for-prostate-cancer-auaastrosuo-guideline-part-i